V.1 UCSF Health Guidance for Adult COVID-19 Pre-Exposure Prophylaxis (passive immunity) Author: Adult COVID-19 Monoclonal Antibody Use Task Force

5/24/2024

Background: On March 22, 2024, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for pemivibart (Pemgarda[™]) for use as pre-exposure prophylaxis (prevention) of COVID-19 in eligible immunocompromised patients who are not currently infected nor exposed to COVID-19.

This drug is not a substitute for vaccination, and all patients who can receive vaccination should do so. This document contains information about how the drug will be allocated to adults at UCSF Health.

For other COVID-19 therapeutics, refer to the UCSF Adult COVID-19 treatment website here.

Important Information: Consider prior to ordering pemivibart and discuss with your patient:

- EUA authorization is based on immunobridging studies
- Clinical Data are limited
- Newer mAb for PrEP are under investigation and may be EUA authorized by July 2024
- High incidence of infusion related and hypersensitivity reactions (up to 9%), along with 0.6% rate of anaphylaxis
- The medication + infusion clinic visit will be billed to insurance. Unlike tixagevimab/cilgavimab, pemivibart is not free.

Data re: pemivibart and rationale for its EUA authorization

<u>Scientific Publications</u> <u>FDA Pemgarda FAQ</u> <u>Pemivibart Patient Fact Sheet</u> Pemivibart Package Insert

Dosing of Pemivibart and Timing with COVID-19 vaccination

- Initial dose 4500mg IV, infused over 1-hour
 - Requires 2-hour monitoring period after infusion in the infusion center
 - Requires premedication for prevention of hypersensitivity/infusion reaction (included in therapy plan)
- Requires repeat dosing every 3 months
- Pemivibart must be separated by 2 or more weeks after COVID-19 vaccination

Prior Authorization required prior to scheduling

- Referring clinical team must obtain prior authorization for the following codes:
 - M0224 administration code
 - Q0224 product/drug code
- Patients should be counseled on potential cost-sharing of medication and infusion clinic visit

Definitions

CDC Description of Moderate and Severe Immunocompromising Conditions and Treatment / Not expected to mount an adequate immune response to complete vaccination

Inclusion Criteria for Pemivibart

Moderate and severe immunocompromising conditions and treatments include but are not limited to:

- Active treatment for solid tumor and hematologic malignancies
- Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia)
- Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy
- Receipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic cell transplant (HCT) (within 2 years of transplantation or taking immunosuppressive therapy)
- Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome)

V.1 UCSF Health Guidance for Adult COVID-19 Pre-Exposure Prophylaxis (passive immunity) Author: Adult COVID-19 Monoclonal Antibody Use Task Force

5/24/2024

- Advanced HIV infection (people with HIV and CD4 cell counts less than 200/mm3, history of an AIDSdefining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) or untreated HIV infection
- Active treatment with high-dose corticosteroids (i.e., 20 mg or more of prednisone or equivalent per day when administered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell-depleting agents)

Intended Population for Pemivibart

Due to pemivibart's limited efficacy data, safety profile, and the current COVID-19 climate (low-level community spread, existing immunity, effective treatment options), suggest limiting administration of pemivibart to those at highest risk for severe COVID-19 infection.

Inpatient, Adults

1. Pemivibart will not be offered in the inpatient setting

Outpatient, Adults

- 1. Hematologic Malignancy Diagnosis
 - a) Diagnosis of AML or ALL on active treatment, or have received cytotoxic chemotherapy in the past 3 months
 - b) CAR T-cell or alloHCT in the past 3 months
 - c) Not on a research study unless approval documented by study PI
- 2. Receiving B-cell depleting agents actively or with persistent substantial B-cell depletion from recent prior B-cell depleting therapy
- 3. Primary Immunodeficiency Diagnosis
 - a) Combined immunodeficiencies (eg SCID/CVID), B-cell deficiencies, and/or needing immunoglobulin replacement, idiopathic CD4 lymphopenia/severe lymphopenia
 i. But NOT CGD or most DiGeorge's syndrome
- 4. May consider in other severe immunocompromising conditions or treatments as noted in description above and per CDC criteria

Other requirements

- 1. Received at least 1 dose of CDC-approved monovalent or ineligible for COVID19 vaccination
- 2. 2-weeks or more after receipt of last COVID19 vaccine
- 3. EUA and risk, benefit, alternatives reviewed with patient
- 4. No evidence of active COVID19 infection

Exclusion Criteria for Pemivibart

- 1. COVID19 vaccination in the past 2-weeks
- 2. Active COVID19 infection
- 3. Previous reaction to pemivibart or COVID-19 vaccine

Outpatient PrEP Workflow:

- 1) Send patient the "**COVIDPemivibartPatient**" smartphrase in a mychart message or into AVS or mail to the patient.
 - a. This smartphrase includes a link to Patient Fact Sheet which the patient must review
 - b. Counsel the pt on EUA risks/benefits/cost
 - c. Inform pt that a 2-hour monitoring period is required after each infusion
 - d. Educate pts that they remain at risk for COVID19 infections despite pemivibart
 - e. Obtain PA (see #2)

V.1 UCSF Health Guidance for Adult COVID-19 Pre-Exposure Prophylaxis (passive immunity) Author: Adult COVID-19 Monoclonal Antibody Use Task Force 5/24/2024


- 2) REF800: order + sign
 a. Enables PA process for 2 codes (1) M0224 : administration code (2) Q0224 : product/drug code
- 3) Pemivibart therapy plan: order + sign
 - a. Open encounter where orders can be placed > Therapy Plan tab > Monoclonal Antibodies > Pemivibart > complete + sign*
 - b. if both are not done, the pt will not be scheduled
- 4) How to order <u>Video</u> [passcode: x77!D9Nf]
- 5) Pictures of orders
 - a. Therapy Plan:

Trishul Auto-Adult Legal: Testfour Auto-Adult Male, 30 y.o. 3/1/1994 Pronoum: he/him/his	Plan Summary Intransfruence - Tressure Plans Anti-Infectives Biologic Therapy	Monoclonal Antibodies No assigned therapy plan MONOCLONAL ANTIBODIES		
MRN: 97810117 Language: English Bed: 10IC-1	Bone Meds BMT			1 Previous 8 No
Code: Not on file No ACP	BCH OAK Cath Cyclophosphami Dialysis	Radiopharmaceutical		
COVID Results/Vaccine Summary Richard L Caplin, MD	Electrolytes Enzyme Replace Epoprostenol	Radiopharmaceutical		
PCP Coverage: Blue Shield/Affinity M	Growth Factors/ Injections	Steroids		
Allergies: No Known Allergies	Iron Replacement IV Flush/Hydratio IVIG/HBIG	+ STEROIDS		
None REASON FOR VISIT	Monocional Antib Radiopharm	🚊 Therapeutic Phlebotomy 💉		
Weight: 69.9 kg (154 lb) Care Gaps: 93	Steroids Therapeutic Phie Transfusion	No assigned therapy plan THERAPEUTIC PHLEBOTOMY		
LAST 3YR 9g No visits	Uniogy АниелевияРнопониелеви Тнелили Риала	Transfusion		
A No results Last CrCI: None	Ht.Wt.Dose Calc Apheresis-pediat	No assigned therapy plan TRANSFUSION		
HEM ONC PROBLEMS (0) Other problems (0)	Apheresis-adult t Apheresis-adult s Photopheresis	≘ Urology ≠		
Social Determinants of Health:		No assigned therapy plan UROLOGY		
e Vi 🗅		- Vital Signs 🕜		
		+ New Reading		Flowsh
			Admission (Current) from 3/1/2024 5/29/2024 1100	In TINE CARD ICU
		Height and Weight		
	. بر	vregm Drug Dosing Weight	09.004 Ag (154 bg) 69.854 kg (154 bb)	
		+ ADD DX (0)		✓ sign

V.1 UCSF Health Guidance for Adult COVID-19 Pre-Exposure Prophylaxis (passive immunity) Author: Adult COVID-19 Monoclonal Antibody Use Task Force 5/24/2024

in Not Signed			
AMB PEMIVIBART (PEMGARDA) COVID-19 PROPHYLAXIS - (EUA USE) - ADULT	Interval D	ration Due Last	Released
Not Signed			
Nursing Instructions Care Order to Nursing Not Otherwise Specified See Below	Every visit	 Every visit 	
Once, Starting when released Spacify communication. See Below Clinician to contact for questionn/issues (via Voaite). ***			
Q Qkay to Treat Order (adult)	Every visit	 Every visit 	
Pemivibart must be separated by 2 weeks or more after the most recent COVID19 vaccine			
Pre-Medications @ acetaminophen (TYLENOL) tablet 650 mg	Every visit	 Every visit 	
656 mg, Oral, Once, 1 dose, Starting when released Administer 15-66 minutes BEFORE penvilvant Refet to Recommunication tais in MAR for clady maximum.		0	
Cetirizine (ZYRTEC) tablet 10 mg	Every visit	 Every visit 	
II 10 mg, Oral, Once, 1 dose, Starting when released Administer 15-60 minutes BEFORE pemivibart.			
famotidine (PEPCID) tablel 20 mg 20 mg, Oral, Once, 1 dose, Starting when released	Every visit	 Every visit 	
Administer 15-60 minutes BEFORE penivibart.	Every visit	 Every visit 	
Comparison of the descence of the second secon		0	
Medication Medication penivibart (PEMGARDA) 4,500 mg in sodium chloride 0.9 % 50 mL IVP8	Every visit	 Every visit 	
4.500 mg_Intravenous_at.50 mL/hr_Administer over 60 Minutes Once 1.dose_Starling when released			
Jose can be givin every 3 or more months. Once infusion is complete flush line with 0.9% sodium chloride. Observe patients for at least 2 hours after infusion is complete Keep Represented Unit Use. Infuse through a 0.2 micron in-line litter.			
Comparison of the second			
diphenhydrAMINE (BENADRYL) injection 25-50 mg 55 E0 ms temperature DN injection 25-50 mg	Every visit	 Every visit 	
2-So mg, imaximuos, one ren, uncara, purso or reneration or even associated with permittant administration, starting when released, clinic loss dipenhydraMINE (BENARRY, BANCPHEN) capsule 25-50 mg 25-50 mg, One PRN, uticalis, pursis, or shortness of breach associated with permitibart administration, Starting when released, Unit Discontinue	Every visit	 Every visit 	
the process of the proces of the process of the process of the process of the process of th	eo Every visit	 Every visit 	
100 mg. Intravenous Once FRN, intravia, jouritis, or shortness of breath associated with pemivibart administration. Starting when released. Until Discontinued Protect from light.			
II 2 albuterol (PROVENTIL HFA;VENTOLIN HFA) 90 mcg/actuation inhaler 2 puff	Every visit	 Every visit 	
^{III} 2 puff, Inhalation, Once PRN, Shortness of Breath, or chest tightness associated with perivibart administration, Starting when released, Until Discontinu IDD DX (0)	ued		
Order and SmartSet Search REF800 P GrantSets, Panels, & Express Lanes (No results found)			
REF800 9 El SmartSets, Panels, & Express Lanes (No results found)			
REF800 E SmartSets, Panels, & Express Lanes (No results found) After Visit Medications (No results found) After Visit Procedures	ype Px Code	Resul	ting
REF800 9 El SmartSets, Panels, & Express Lanes (No results found) C After Visit Medications (No results found) C After Visit Procedures * Name Prequency Ty O Referral to Infusion Service Ref	ype Px Code eferral REF800	Resul	lting
REF800 I SmartSets, Panels, & Express Lanes (No results found) After Visit Medications (No results found) After Visit Procedures * Name Frequency Ty		Resul	Iting
P III SmartSets, Panels, & Express Lanes (No results found) III After Visit Medications (No results found) III After Visit Procedures * Name Prequency III Referral to Infusion Service		Resul	iting
P El SmartSets, Panels, & Express Lanes (No results found) Image: After Visit Medications (No results found) Image: After Visit Procedures A Name Prequency Image: After Visit Influsion Service Referral to Influsion Service Referral to Influsion Service Referral to Influsion Service Referral to Influsion Service		Resul	ting
P III SmartSets, Panels, & Express Lanes (No results found) III After Visit Medications (No results found) III After Visit Procedures * Name Prequency III Referral to Infusion Service		Resu	iting
P El SmartSets, Panels, & Express Lanes (No results found) Image: After Visit Medications (No results found) Image: After Visit Procedures A Name Prequency Image: After Visit Influsion Service Referral to Influsion Service Referral to Influsion Service Referral to Influsion Service Referral to Influsion Service			iting
P El SmartSets, Panels, & Express Lanes (No results found) Image: After Visit Medications (No results found) Image: After Visit Procedures A Name Prequency Image: After Visit Influsion Service Referral to Influsion Service Referral to Influsion Service Referral to Influsion Service Referral to Influsion Service	eferral REF800		ting
REF800 P If SmartSets, Panels, & Express Lanes (No results found) Image: After Visit Medications (No results found) Image: After Visit Procedures & Prequency Ty Image: Name Prequency Ty Image: Referral to Infusion Services	eferral REF800		
REF800 P If SmartSets, Panels, & Express Lanes (No results found) After Visit Medications (No results found) Image: After Visit Procedures * Prequency Ty Image: Name Prequency Ty Image: Referral to Infusion Service Referral to Infusion Service Image: Referral to Infusion Service Referral to Infusion Service Image: Referral to Infusion Service Referral to Infusion Service Image: Referral to Infusion Service Referral to Infusion Service Image: Referral to Infusion Service Referral to Infusion Service	eferral REF800	h	
REF800 P If SmartSets, Panels, & Express Lanes (No results found) Image: After Visit Medications (No results found) Image: After Visit Procedures & Prequency Ty Image: Name Prequency Ty Image: Referral to Infusion Services	eferral REF800	h	
REF800 P El SmartSets, Panels, & Express Lanes (No results found) After Visit Medications (No results found) Image: After Visit Medications (No results found) Image: After Visit Procedures * Name Name Prequency Image: After Visit Procedures * Name Prequency Image: After Visit Procedures * Name Prequency Image: After Visit Procedures * Name Prequency Image: After Visit Procedures (No results found) Referral to Infusion Services Class: UCSF UCSF Image: Outpoing Referral MarinHealth Referral: Priority:	eferral REF800	h	
REF800 P II SmartSets, Panels, & Express Lanes (No results found) After Visit Medications (No results found) In After Visit Procedures * Prequency Ty Name Prequency Ty Referral to Infusion Services Referral to Infusion Services Class: UCSF Outgoing Referral MarinHealth Referral: Priority: Routine Pointer	eferral REF800	h	
REF800 P II SmartSets, Panels, & Express Lanes (No results found) After Visit Medications (No results found) Image: After Visit Procedures * Prequency Ty Name Prequency Ty Referral to Infusion Services Referral to Infusion Services Referral to Infusion Services Referral to Infusion Services Class: UCSF UCSF Outgoing Referral MarinHealth Referral: Priority: Routine Routine Urgent Reason for Referral: See Beacon See Thorapy Plan Vaccine Remdesivir Other RegimentDrug Name pemivibart See Thorapy Plan Vaccine Remdesivir Other	eferral REF800	h	
REF800 P II SmartSets, Panels, & Express Lanes (No results found) After Visit Medications (No results found) In After Visit Procedures * Prequency Ty Name Prequency Ty Referral to Infusion Services Referral to Infusion Services Class: UCSF Outgoing Referral MarinHealth Referral: Priority: Routine Pointer	eferral REF800	h	
REF800 P El SmartSets, Panels, & Express Lanes (No results found) After Visit Medications (No results found) After Visit Medications (No results found) Prequency Ty After Visit Procedures * Prequency Ty Name Prequency Ty Referral to Infusion Services Referral to Infusion Services Class: UCSF UCSF Outgoing Referral MarinHealth Referral: Priority: Routine Routine Urgen Reason for Referrat: See Beaco See Therapy Plan Vaccine Remdesivir Other RegimentDrug Name Referred from specially: Hematology Solid Oncology Non-Oncology Is treatment part of research protocol? Solid Oncology Non-Oncology	eferral REF800	h	
REF800 P If SmartSets, Panels, & Express Lanes (No results found) After Visit Medications (No results found) Image: After Visit Medications (No results found) Image: After Visit Procedures A (No results found) Image: Name (No results found) Image: After Visit Procedures A (No results found) Image: Name (No results found) Image: After Visit Procedures (No results found) Image: Name (No results found) Image: After Visit Procedures (No results found) Image: No results found) Image: After Visit Procedures (No results found) Image: No results found) Image: After Visit Procedures (No results found) Image: No results found) Image: After Visit Procedures (No results found) Image: No results found) Image: After Visit Procedures (No results found) Image: No results found) Image: After Visit Procedures (No results found) Image: No results found) Image: After Visit Procedures (No results found) Image: No results found) Image: After Visit Procedures (No results found) Image: No results found (No results found) Image: After Visit Procedures (No results found) Image: No results found (No resul	eferral REF800	h	
REF800 P El SmartSets, Panels, & Express Lanes (No results found) After Visit Medications (No results found) After Visit Medications (No results found) Prequency Ty After Visit Procedures * Prequency Ty Name Prequency Ty Referral to Infusion Services Referral to Infusion Services Class: UCSF UCSF Outgoing Referral MarinHealth Referral: Priority: Routine Routine Urgen Reason for Referrat: See Beaco See Therapy Plan Vaccine Remdesivir Other RegimentDrug Name Referred from specially: Hematology Solid Oncology Non-Oncology Is treatment part of research protocol? Solid Oncology Non-Oncology	eferral REF800	h	ncel
REF800 El SmartSets, Panels, & Express Lanes (No results found) After Visit Medications (No results found) After Visit Medications (No results found) After Visit Procedures * Name Prequency Ty Referral to Infusion Services Class: UCSF UCSF UCSF Outgoing Referral MarinHealth Referral: Referral: Priority: Routine Reson for Referral: See Beacon See Therapy Plan Vaccine Remdesivir Other RegimentDrug Name pemivibart Referred from specially: Hematology Solid Oncology Is treatment part of research protocol? Yes No Referred to location: ITANSFEUSION PARM	eferral REF800	h ✓ Accept X ⊆au	ncel
REF800 El SmartSets, Panels, & Express Lanes (No results found) After Visit Medications (No results found) After Visit Procedures Name Frequency Referral to Infusion Services Class: UCSF UCSF UCSF Outgoing Referral MarinHealth Referrat: Priority: Results found) Referrat: Referrat: See Beacon See Therapy Plan Vaccine Remdesivir Other RegimentDrug Name pemivibart Referred from specially: Hematology Solid Oncology Non-Oncology Is treatment part of research protocol? Yes No	eferral REF800	h ✓ Accept X ⊆au	ncel
REF800 El SmartSets, Panels, & Express Lanes (No results found) After Visit Medications (No results found) After Visit Medications (No results found) After Visit Procedures * Name Prequency Ty Referral to Infusion Services Class: UCSF UCSF UCSF Outgoing Referral MarinHealth Referral: Referral: Priority: Routine Reson for Referral: See Beacon See Therapy Plan Vaccine Remdesivir Other RegimentDrug Name pemivibart Referred from specially: Hematology Solid Oncology Is treatment part of research protocol? Yes No Referred to location: ITANSFEUSION PARM	eferral REF800	h ✓ Accept X ⊆au	ncel
REF800 El SmartSets, Panels, & Express Lanes (No results found) After Visit Medications (No results found) After Visit Medications (No results found) After Visit Procedures * Name Prequency Ty Referral to Infusion Services Class: UCSF UCSF UCSF Outgoing Referral MarinHealth Referral: Referral: Priority: Routine Reson for Referral: See Beacon See Therapy Plan Vaccine Remdesivir Other RegimentDrug Name pemivibart Referred from specially: Hematology Solid Oncology Is treatment part of research protocol? Yes No Referred to location: ITANSFEUSION PARM	eferral REF800	h ✓ Accept X ⊆au	Incel

V.1 UCSF Health Guidance for Adult COVID-19 Pre-Exposure Prophylaxis (passive immunity) Author: Adult COVID-19 Monoclonal Antibody Use Task Force 5/24/2024



A	location					
Guiding principles						
٠	No patient should be denied access to pre-exposure prophylaxis based on age, disability, religion, race,					
	ethnicity, national origin, immigration status, gender/gender identity, perceived quality of life, or sexual					
	orientation					

• Patients eligible for pre-exposure prophylaxis via clinical trials should be offered participation in the trials (if available) but should not be compelled to participate in trials for the sole purpose of accessing the drug. Patients who opt not to participate in trials shall be offered pre-exposure prophylaxis via the EUA if eligible

Process

Among individuals eligible for receipt of the agent by the guidelines above, allocation will occur as outlined in the detailed COVID Monoclonals Allocation Guidance document when drug supply is limited *need to get this document